Allergan plc (AGN) Shares Sold by Bank of Hawaii

Bank of Hawaii reduced its stake in shares of Allergan plc (NYSE:AGN) by 14.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,198 shares of the company’s stock after selling 1,941 shares during the quarter. Bank of Hawaii’s holdings in Allergan were worth $1,832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in AGN. Cable Hill Partners LLC grew its holdings in Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its holdings in Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares in the last quarter. BB&T Investment Services Inc. grew its holdings in Allergan by 1,308.2% during the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after buying an additional 641 shares in the last quarter. Acropolis Investment Management LLC purchased a new stake in Allergan during the 4th quarter valued at approximately $153,000. Finally, Field & Main Bank purchased a new stake in Allergan during the 4th quarter valued at approximately $155,000. 79.66% of the stock is owned by institutional investors and hedge funds.

In other Allergan news, Chairman Brent L. Saunders bought 4,600 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matthew M. Walsh bought 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were acquired at an average price of $160.94 per share, with a total value of $321,880.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 19,630 shares of company stock valued at $3,211,937. 0.36% of the stock is owned by corporate insiders.

A number of research firms have recently commented on AGN. Credit Suisse Group increased their target price on Allergan from $214.00 to $215.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Bank of America increased their target price on Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Leerink Swann increased their target price on Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reiterated a “hold” rating and set a $191.00 target price on shares of Allergan in a research report on Tuesday, February 6th. Finally, ValuEngine downgraded Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $227.23.

Shares of Allergan plc (NYSE:AGN) opened at $159.40 on Friday. The stock has a market capitalization of $52,620.00, a price-to-earnings ratio of -13.29, a P/E/G ratio of 1.14 and a beta of 1.19. Allergan plc has a 52-week low of $156.00 and a 52-week high of $256.80. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.88.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. Allergan’s revenue was up 12.0% on a year-over-year basis. During the same period last year, the company earned $3.90 earnings per share. analysts anticipate that Allergan plc will post 15.57 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 1.81%. Allergan’s dividend payout ratio (DPR) is currently -23.35%.

TRADEMARK VIOLATION NOTICE: “Allergan plc (AGN) Shares Sold by Bank of Hawaii” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/23/allergan-plc-agn-shares-sold-by-bank-of-hawaii.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply